September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
Sep 11, 2025, 13:37

Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial

National Bleeding Disorders Foundation shared on LinkedIn:

”Promising news for the hemophilia community!

Pfizer’s HYMPAVZI™ (marstacimab-hncq) shows a 93% reduction in treated bleeds in its Phase 3 trial for people with hemophilia A or B with inhibitors.”

Learn more here.

Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial

Stay updated on the emerging in the field of hemophilia with Hemostasis Today.